|
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good faith efforts to retrieve a reported adverse event/incident-related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.The review confirms there were no manufacturing or processing non-conformities identified that would contribute to the reported adverse event/incident.The device was not returned to endologix for evaluation because it remains implanted.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the type ib endoleak of the right common iliac artery and an additional endovascular procedure is confirmed.This is consistent with the reported adverse event/incident.The complaint is likely anatomy and user-related.At the index procedure, the alto graft was used as an auto-uni-iliac (aui) device due to the inability to cross the right common iliac artery due to preexisting occlusion (off-label use).There was also a preexisting subtotal occlusion of the right common iliac artery (anatomy-related).No procedure-related harms were identified.The final patient status was reported as discharged to home in stable condition on postoperative day two.No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.This adverse event/incident was previously submitted to the fda on 25 march 2025 under the incorrect fe # 3011063223.Please reference 3011063223-2025-00027 for the initial reporting of this adverse event/incident.
|